Navigation Links
NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session
Date:3/28/2008

NEW YORK (March 27, 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American College of Cardiology's 57th Annual Scientific Session in Chicago, March 29 to April 1. Among the most significant presentations are the following:

Drug-Eluting Stents Versus Bare-Metal Stents for Transplant Allograft Vasculopathy

Dr. Jeffrey Moses Director of the Center for Interventional Vascular Therapy and director of the Cardiac Catheterization Lab at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons

Heart transplant patients are more vulnerable to accelerated arteriosclerosis in their transplanted heart than the general population. In one of the largest studies of its kind, NewYork-Presbyterian/Columbia researchers found that drug-eluting stents were able to better keep arteries open and prevent narrowing than bare-metal stents. However, mortality rates for interventions were equal.


The Impact of Mandatory Angiographic Follow-up on the One-Year Clinical and Angiographic Results From Endeavor IV: A Randomized Comparison of the Endeavor Drug (ABT-578) Eluting Stent System vs. Taxus in De Novo Native Coronary Lesions

Dr. Martin B. Leon Associate director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons. He is founder and chairman emeritus of the Cardiovascular Research Foundation in New York City.

This presentation will look at follow-up using angiograms and clinical outcomes on patients in the Endeavor IV study, which compares the Endeavor drug-eluting stent with the Taxus drug-eluting stent. The results indicate that clinical follow-up may be more meaningful in determining the true patient value of drug-eluting stents in preventing restenosis, the closing or narrowing of the previously-opened artery.


Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Baseline Renal Function on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Advanced Age on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Is Diabetes a Risk Factor for Restenosis and Adverse Clinical Outcomes After Paclitaxel-Eluting Stent Implantation: Pooled Analysis of the TAXUS IV and TAXUS V Trials

Dr. Gregg W. Stone Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons. He is also chairman of the Cardiovascular Research Foundation in New York City.

Dr. Stone will present new findings from the HORIZONS AMI trial, which is evaluating the drug bivalirudin for heart attack patients undergoing angioplasty. Last year, investigators reported that the therapy reduces risk of death compared with the standard treatment. New findings look at several subsets, including older patients and patients with diabetes, finding bivalirudin also effective for these groups.

In addition, Dr. Stone will present findings from the TAXUS trials looking at the risk of restenosis and other negative outcomes in patients with diabetes with the Taxus drug-eluting stent.


'/>"/>

Contact: Bryan Dotson
brd9005@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. CVS Caremark Presents at NCOA-ASA Conference on Companys Commitment to Recruiting and Retaining Mature Workers
2. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
3. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
4. Accurays CFO to Present at B. Riley & Company Ninth Annual Investor Conference
5. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
6. Bionovo to Present at the Cambria Capital Investor Meeting
7. UC Irvine researchers present latest findings at emergency medicine forum
8. BD to Present at the Leerink Swann Molecular Diagnostics Roundtable Conference
9. RNR Public Relations Presents Perfect April Fools Day Feature Opportunity
10. Health Fitness to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference
11. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: